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Abstract
Background: Factors associated with liver stiffness (LS) are unknown and normal reference values for LS have not
been established. Individuals at high risk for alcoholic (ALD) and non-alcoholic fatty (NAFLD) liver disease need to
be non-invasively discriminated during routine health checks. Factors related to LS measured using a FibroScan
and normal reference values for LS are presented in this report.
Methods: We measured LS using a FibroScan in 416 consecutive individuals who presented for routine medical
checks. We also investigated the relationship between LS and age, body mass index (BMI), liver function (LF),
alcohol consumption, and fatty liver determined by ultrasonography. We identified individuals at high-risk for ALD
and NAFLD as having a higher LS value than the normal upper limit detected in 171 healthy controls.
Results: The LS value for all individuals was 4.7 +/- 1.5 kPa (mean +/- SD) and LS significantly and positively
correlated with BMI and LF test results. The LS was significantly higher among individuals with, than without fatty
liver. Liver stiffness in the 171 healthy controls was 4.3 +/- 0.81 kPa and the upper limit of LS in the normal
controls was 5.9 kPa. We found that 60 (14.3%) of 416 study participants had abnormal LS. The proportion of
individuals whose LS values exceeded the normal upper limit was over five-fold higher among those with, than
without fatty liver accompanied by abnormal LF test results.
Conclusions: Liver stiffness could be used to non-invasively monitor the progression of chronic liver diseases and
to discriminate individuals at high risk for ALD and NAFLD during routine health assessments.
Background
A large body of evidence supports the importance of
liver biopsies for understanding the progression of
chronic liver disease [1]. Although liver biopsy is the
gold standard for diagnosing chronic liver disease and
for determining the extent of liver fibrosis, adverse
effects and sampling errors are associated with the pro-
cedure [2-7], because a standard liver biopsy samples
only about 1/50,000 of the liver [8]. In addition, the role
of the liver biopsy in nonalcoholic fatty liver disease
(NAFLD) is controversial. Arguments against routine
liver biopsy include the generally benign course of
NAFLD, the absence of established effective therapies
even when findings indicate a need for treatment, and
the risks associated with liver biopsy [9].
To distinguish nonalcoholic steatohepatitis (NASH)
from NAFLD in routine practice is difficult. Efforts have
been made to diagnose NASH using various imaging
studies and blood tests, but the outcome has remained
inadequate [10].
The FibroScan (Echo Sens, Paris, France) is a new
transient elastometer that can noninvasively measure LS
[11,12]. Correlations between LS and fibrosis have been
reported [13,14] and monitoring LS might provide a
method for observing and judging the progression of
chronic liver diseases, including fatty liver disease [15].
* Correspondence: m-baba@piano.ocn.ne.jp
Hokkaido Social Insurance Hospital, Center for Gastroenterology and
Hepatology, Sapporo, Japan
Baba et al. BMC Gastroenterology 2011, 11:70
http://www.biomedcentral.com/1471-230X/11/70
© 2011 Baba et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Various clinical factors other than fibrosis itself,
including necroinflammation of the liver, cholestasis and
congestive heart failure can affect LS regardless of the
severity of fibrosis [13,14]. However, factors influencing
LS in apparently healthy subjects other than liver fibro-
sis have not been sufficiently clarified [16-19]. Almost
all European studies have focused on patients with
chronic liver disease. Although a few studies have evalu-
ated healthy individuals from the viewpoint of defining
normal reference values for LS [16,17], some of those
included might have had subclinical liver disease. There-
fore, normal reference values for of LS still need to be
established based on data from healthy persons who are
considered not to have liver disease at any stage.
The present study explores factors related to LS,
establishes normal reference values for LS in healthy
individuals, and determines whether LS can help to
identify individuals at high-risk for ALD and NAFLD.
Methods
Study population
This study enrolled 423 consecutive Japanese individuals
between the ages of 20 and 68 years (250 males; hepati-
tis B surface antigen negative; hepatitis C virus antibody
negative), who presented for annual medical checkups at
our health examination centre between July 2004 and
April 2006. We excluded individuals with a history of
any liver or cardiac diseases (especially congestive heart
failure) and those who were under treatment for such
conditions. We also excluded those with platelet counts
< 150,000/μL. A medical history was obtained from each
of the 423 persons, who then underwent a physical
examination, a chest X-ray, electrocardiography and
standard laboratory tests including FBS and HbA1c.
Seven were excluded because LS could not be measured
due to extensive intercostal subcutaneous tissue depth.
Finally, 416 individual (250 males) were enrolled in this
study. All participants provided written informed con-
sent to participate in this study, which proceeded
according to the Declaration of Helsinki and under the
approval of our institutional review board.
Abdominal ultrasonography and liver stiffness measured
by transient elastography
We used ultrasonography to diagnose fatty liver based
on hepatorenal contrast visualization, increased ultraso-
nographic signals in the liver parenchyma and decreased
signals from deep areas of the liver. We also confirmed
the absence of space-occupying lesions in the liver. Stiff-
ness was measured in the right lobe of the liver accessed
using a FibroScan through the intercostal spaces of par-
ticipants placed in the dorsal decubitus position with
the right arm in maximal abduction. Technical and pro-
cedural details have been described [13,20]. In brief, the
FibroScan is equipped with a probe that includes an
ultrasonic transducer. The tip of the transducer is cov-
ered with gel and placed on a specific location. A low-
frequency, mild amplitude vibration is transmitted to
the liver from the tip of the transducer. This vibration
induces an elastic shear wave, of which the propagation
and velocity are measured by simultaneous ultrasono-
graphy and expressed in kilopascals (kPa). These proper-
ties are directly related to liver tissue stiffness. Higher
values indicate increased liver stiffness. Up to 10 mea-
surements were obtained from each participant, and LS
is represented as median values. Only procedures with
at least 10 valid measurements, a success rate of at least
60% and an IQR to median value ratio of < 30% were
considered reliable [21]. The success rate and IQR in
this study were 94% and 17%, respectively. The FibroS-
can measures LS in a volume that approximates a 4-cm
long cylinder with a diameter of 1 cm located between
2.5 and 6.5 cm below the skin surface. This volume is
about 100-fold larger than a standard liver biopsy speci-
men, and thus might be more representative of the
entire hepatic parenchyma. Individuals (N = 7) with
intercostal subcutaneous tissues ≥ 25 mm [11-13] were
excluded from the study because liver stiffness could
not be measured under such conditions using the
FibroScan.
Measurement of physical findings and liver function tests
Height and weight were measured and BMI was calcu-
lated. To further assess the impact of body weight, we
assigned the 416 participants into groups based on BMI
< 23, 23 to ≤ 25, and > 25. The thickness of the inter-
costal subcutaneous tissues was measured only to con-
firm whether LS could be measured. Daily amounts and
duration of alcohol consumption were evaluated using a
formal, written questionnaire and total amounts of con-
sumed alcohol were calculated as quantities of pure
alcohol. Since alcohol consumption of ≤ 20 g of per day
is prerequisite for a definition of NASH, we assigned the
416 participants into groups based on daily alcohol con-
sumption of ≤ 20 and > 20 g/day (non-/occasional and
habitual consumption, respectively) [20,22]. Liver func-
tion (LF) was tested in terms of serum levels of aspar-
tate 2-oxoglutarate aminotransferase (AST), alanine
aminotransferase (ALT) and g-glutamyltranspeptidase
(g-GTP). The normal upper limits of AST, ALT and g-
GTP at our health centre are 35, 35 and 55 U/L, respec-
tively. We defined normal LF tests results as each of
AST, ALT and g-GTP being within normal limits.
Influence of liver dysfunction and fatty liver on LS
The participants were separated based on LF tests
results and the presence or absence of fatty liver into
Group 1 (N = 260), normal LF and no fatty liver; Group
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2 (N = 32), abnormal LF and no fatty liver; Group 3 (N
= 60), normal LF and fatty liver; Group 4 (N = 59),
abnormal LF and fatty liver.
Relationship between LS and platelet counts or platelet
ratio index
We counted platelets and calculated the AST to platelet
ratio index (APRI) to determine the relationship
between LS and apparent liver fibrosis in all participants
[23].
Determination of normal reference values for liver
stiffness
We selected healthy control candidates based on the fol-
lowing criteria: BMI < 23 kg/m2, normal LF, no findings
of fatty liver by ultrasonography and daily alcohol con-
sumption ≤ 20 g/day. We defined being overweight and
obesity based on the World Health Organization
(WHO) criteria for the Western Pacific Region as BMI
≥ 23 and ≥ 25 kg/m2, respectively [22,24]. None of our
healthy control candidates fulfilled the criteria for meta-
bolic syndrome proposed by International Diabetes Fed-
eration [25]. Furthermore, to establish normal reference
values based on stricter criteria, candidates had to meet
any one of the following conditions: triglycerides, < 150
mg/dL; HDL cholesterol, ≥ 40 mg/dL in men and ≥ 50
mg/dL in women; blood pressure, < 130/85 mmHg and
fasting plasma glucose, < 100 mg/dL. We excluded six
candidates because of high blood pressure. We finally
selected 165 (77 males) of the 416 participants who met
the criteria described above as normal controls
(Figure 1)
Statistical analysis
Continuous variables are expressed as means ± SD. The
relationship between LS and each variable was assessed
using Pearson’s correlation coefficient and LS was com-
pared between two groups using the unpaired Student’s
t-test. Differences among more than three groups were
analyzed using the analysis of variance (ANOVA) when
variables were normally distributed, followed by multiple
comparisons. Categorical data were compared using the
c2 test and the Cochran-Armitage test for trends. Both
univariate and multivariate analyses were performed
using logistic regression models. P < 0.05 was consid-
ered to represent a statistically significant difference.
Data were statistically analysed using JMP 9.01 software
(SAS Institute Inc., Cary, NC).
Results
Table 1 shows the background characteristics of all par-
ticipants and controls. The value for LS in all (N = 416)
participants was 4.73 ± 1.54 kPa (range, 2.3-18.6 kPa)
and that in healthy controls (N = 165) was 4.30 ± 0.81
kPa (range, 2.7-7.4 kPa) with a normal upper limit of
5.9 kPa (mean + 2SD). Liver stiffness tended to increase
with age in all participants, although the difference did
not reach statistical significance (p = 0.11).
Liver stiffness values were significantly higher in males
than in females among all participants (4.88 ± 1.77 vs.
4.52 ± 1.11 kPa, respectively, p = 0.02), but did not signif-
icantly differ between healthy control males and females
(4.41 ± 0.79 vs. 4.20 ± 0.83 kPa, respectively, p = 0.10).
Liver stiffness significantly correlated with BMI in all
participants (Table 2). Mean LS based on BMI (ANOVA
p < 0.0001; Figure 2) and the proportion of those with
LS beyond the normal upper limit (x2 = 14.31, p =
0.0008) also significantly differed among the three
groups. The Cochran-Armitage test for trend also
showed a linear trend for proportions across these
groups (Z = 3.84, p < 0.0001).
Figure 1 Flow diagram of study protocol. Seven individuals were
excluded because LS could not be measured due to extensive
intercostal subcutaneous tissue. We excluded 250 individuals based
on four criteria and selected 165 healthy controls from the included
population.
Table 1 Characteristic of all subjects and controls
All subjects Controls
Case(M/F) 416(250/168) 165(77/88)
Age(years) 47.4 ± 13.6 45.1 ± 14.4
BMI(kg/m2) 22.1 ± 3.1 20.2 ± 2.0
BW(kg) 60.1 ± 11.4 53.6 ± 8.3
Thickness of subcutaneous tissue(cm) 1.5 ± 0.4 1.2 ± 0.3
Alcohol consumption(g/day) 30.2 ± 44.3 6.3 ± 4.1
AST(U/L) 23.1 ± 10.9 20.4 ± 4.0
ALT(U/L) 23.5 ± 16.4 19.0 ± 6.6
gGTP(U/L) 40.6 ± 41.7 23.7 ± 10.5
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Values for LS were significantly higher among indivi-
duals with, than without fatty liver. Ratios of those with
LS above normal upper limit significantly differed (x2 =
37.54, p < 0.0001; Figure 3).
Liver stiffness did not correlate with daily or total
alcohol consumption (Table 2) and did not signifi-
cantly differ between those with no or occasional alco-
hol consumption, and those with habitual
consumption. However the ratio of those with LS
above the normal upper limit was significantly higher
in the group who habitually consumed alcohol (x2 =
7.15, p = 0.008; Figure 4).
Liver stiffness significantly and positively correlated
with levels of AST or ALT, and with APRI but not with
g-GTP (Table 2) or platelet counts in all participants.
We found that 60 (14.3%) of the 416 participants had
higher LS. We also found that LS significantly differed
between the presence and absence of fatty liver
(ANOVA, p < 0.0001) when the participants were
assigned to four groups based on the results of LF tests.
In addition, LS was the highest in Group 4, and higher
in Group 3 than in Group 1 according to multiple com-
parisons (Figure 5). Nineteen (7.1%), 4 (12.5%), 14
(23.3%) and 23 (39.0%) participants in Groups 1, 2, 3
and 4, respectively, had LS values above the normal
upper limit and the proportions significantly differed
Table 2 The relationship between liver stiffness and










Alcohol consumption(g/day) 0.011 0.07
Alcohol consumption(total) 0.023 0.64
AST(U/L) 0.231 < 0.0001
ALT(U/L) 0.346 < 0.0001
gGTP(U/L) 0.078 0.11
Plt(× 104/μL) 0.001 0.38
APRI 0.11 < 0.0001
Figure 2 Comparison of liver stiffness among three groups
based on BMI. Mean LS significantly differed among groups and
were corrected for multiple comparisons according to Tukey’s test.
Proportions of individuals with LS above normal upper limit
significantly differed (c2 test and Cochran-Armitage test for trends).
Figure 3 Comparison of liver stiffness based on presence or
absence of fatty liver. Values for LS were significantly higher
among individuals with, than without fatty liver. Ratios of those with
LS above normal upper limit significantly differed (c2 test).
Figure 4 Comparison of liver stiffness between two groups
based on alcohol consumption. Liver stiffness did not significantly
differ between non/occasional and habitual consumption groups.
However, ratios of those with higher LS than normal upper limit
were significantly higher in habitual, than in non/occasional group
(c2 test).
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among the four groups (x2 = 37.54, p < 0.0001). The
Cochran-Armitage test for trend also showed a linear
trend in proportions across the four groups (Z = 6.48, p
< 0.0001; Figure 6).
Figure 7 shows a comparison of liver stiffness among
four groups based on alcohol consumption and fatty
liver. All participants were assigned to two groups based
on alcohol consumption and then each group was sub-
divided into two groups based on the presence or
absence of fatty liver according to ultrasonography
(Groups A, B, C and D). About 7% (6.9% and 7.5%) of
all participants had LS above 5.9 kPa among those with
NAFLD or ALD regardless of fatty liver. We could not
exclude subclinical fatty changes that were undetectable
by ultrasonography in Groups A and C. We thus specu-
lated that liver stiffness can discriminate hepatic
abnormalities more effectively than conventional
ultrasonography.
Univariate analysis found that BMI, alcohol consump-
tion, abnormal LF test results, fatty liver and APRI were
associated with LS.
We excluded abnormal LF test results and fatty liver
as confounding factors in multivariate analysis because
these can result from a higher BMI or habitual alcohol
consumption. We also excluded APRI because this
merely reflected serum levels of AST in this study popu-
lation. Finally, we included BMI and alcohol consump-
tion in the multivariate analysis model.
Multivariate analysis revealed that BMI (23 - 25 kg/
m2: odds ratio (OR), 2.21; 95% confidence interval (CI),
1.06-4.46; p = 0.033; ≥ 25 kg/m2: OR, 3.25; 95% CI,
1.62-6.43; p = 0.001) was the only independent predictor
of higher LS (Table 3).
Discussion
We described factors related to LS and defined normal
reference values for liver stiffness among healthy control
individuals. We also showed that individuals at high risk
for ALD and NAFLD could be discriminated by measur-
ing LS using a FibroScan, which is useful for assessing
Figure 5 Comparison of liver stiffness among four groups based on liver dysfunction and fatty liver. Liver stiffness significantly differed
among these groups. Liver stiffness was highest in Group 4 and that of Group 3 was higher than that of Group 1 according to multiple
comparisons (Tukey’s test).
Figure 6 Ratios of individuals in four groups with liver stiffness
beyond normal upper limit. Ratios of individuals with LS beyond
the normal upper limit significantly differed (c2 test and Cochran-
Armitage test for trend).
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patients with confirmed chronic liver disease [26]. How-
ever, few studies have examined its relevance to a first-
line diagnosis of liver disorders and to identifying
patients at high risk during routine medical checks.
The present study found no significant statistical dif-
ferences between healthy control males and females,
although all enrolled participants significantly differed.
Whether gender should be taken into account when
interpreting liver stiffness has been disputed, because
several confounders between gender and BMI, metabolic
syndrome, and alcohol consumption have not been
appropriately adjusted [16,17,19].
We investigated which factors are related to LS before
determining the normal upper limit of LS. Factors asso-
ciated with LS in all participants were BMI, the presence
of fatty liver, alcohol consumption and serum levels of
AST and ALT. These findings suggested that being
overweight (including obesity), habitual alcohol con-
sumption and abnormal LF test results are important
factors associated with a higher LS. We then selected
those who met our criteria for normal controls based on
these findings.
One of the major reasons for the higher LS in indivi-
duals with a high BMI seemed to be liver steatosis
caused by NAFLD or ALD. Mean liver stiffness was
higher in individuals with, than without fatty liver, but
the distribution of LS widely overlapped between the
two groups. We speculated that factors in addition to
steatosis would be involved in increased LS. We consid-
ered that the mechanisms involved in the increase in
the LS in our study population might be related to
inflammatory cell invasion, liver cell degeneration and
liver fibrosis as well as steatosis, all of which have been
pathologically demonstrated in patients with NASH and
ALD [27]. Whether or not simple steatosis alone would
increase LS remains to be resolved.
The normal upper limit of LS was determined based
on patients with a BMI < 23 kg/m2 in this study. How-
ever, if the upper limit was based on the WHO global
criteria for obesity of BMI ≥ 25 kg/m2, [28], then LS
and the upper limit of LS in controls would be 4.44 ±
1.05 and 6.5 kPa, respectively.
Daily or total alcohol consumption significantly and
positively correlated with g-GTP levels in our study
population (data not shown) as described [29,30]. The
absence of correlations between LS and daily or total
alcohol consumption can be explained by individual
genetic differences in alcohol metabolism and the pre-
sence of a higher LS in patients with NAFLD [23,31].
The ratio of individuals with LS beyond the normal
upper limit was significantly higher among those who
habitually consumed alcohol than in those who did not
consume, or who occasionally consumed alcohol. There-
fore, alcohol consumption seems to be an important
Figure 7 Comparison of liver stiffness among four groups based on alcohol consumption and fatty liver. All participants were assigned
to two groups based on alcohol consumption and then each group was further divided into two subgroups with or without fatty liver
according to ultrasonography (Groups A, B, C, D). About 7% (6.9% and 7.5%) of all participants had LS above 5.9 kPa among those with NAFLD
or ALD regardless of fatty liver.
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factor that affects LS. Although a normal upper limit of
LS was established for participants who consumed ≤ 20
g of alcohol/day, LS and the upper limits of LS in con-
trols (N = 91 of 165) who did not consume alcohol
were 4.15 ± 0.66 and 5.5 kPa, respectively. This normal
upper limit of LS was essentially equivalent to that
reported by Kim et al. We considered that to determine
the effect of consuming a very small amount of alcohol
on LS in this population would be almost impossible, so
we adopted alcohol consumption criteria of ≤ 20 g/day.
The present study found that LS was related to AST
and ALT levels or APRI, which significantly correlates
with stage of fibrosis and with a higher correlation coef-
ficient than platelet count or AST levels alone in
patients with chronic hepatitis C infection [32]. Because
our study population was limited to individuals who
presented for annual medical checkups, LS was more
closely correlated with AST than with APRI, and did
not associate with platelet counts. Liver damage that
causes AST/ALT elevation also appeared to influence
LS, because LS is higher even in patients with acute
viral hepatitis but without liver fibrosis [33].
Univariate analysis indicated that BMI, alcohol con-
sumption, LF test results and fatty liver status were
associated with LS. Among these, the three BMI cate-
gories were significantly associated with fatty liver (c2 =
100.69, p < 0.0001). Alcohol consumption also signifi-
cantly associated with abnormal LF test results (c2 =
26.8, p < 0.0001). We assumed that being overweight
and habitual alcohol consumption can cause abnormal
LF tests results and fatty liver, so BMI and alcohol con-
sumption were included in the multivariate logistic
regression model. Finally, BMI was identified, as the
only independent predictor of higher LS and LS was sig-
nificantly higher even in the group with BMI 23 - 25
kg/m2. Although interpreting LS might be subject to
ethnic differences, we considered that our BMI criteria
were appropriate for inclusion among normal reference
values. Cobbold et al. have highlighted some issues
regarding LS and BMI [19].
Table 4 summarizes two published reports and our
study. Roulot et al. [16] examined a large cohort of
apparently healthy individuals with no evidence of liver
disease and established normal liver stiffness values
(5.60 ± 1.30 kPa in males, 5.05 ± 1.49 kPa in females.
Although their normal upper limit of liver stiffness were
relatively high and almost corresponded to METAVIRE
fibrosis stage 2 (LS = 7.2 kPa) [14,19].
Kim et al. [17] established a normal liver stiffness
value (4.5 ± 0.4 kPa) based on a study of 69 healthy
liver and kidney donors who passed screening evalua-
tions for transplantation, whose laboratory findings
were normal, and who could be regarded as being
healthy and free of liver disease. Our normal upper
limits of liver stiffness were nearly equivalent to
theirs, which was lower than that of Roulot et al. The
study population and criteria for healthy controls
shown in Table 4 probably can account for these
differences.
Liver disorders are usually screened during routine
medical checkups or in clinical practice using LF tests
and ultrasonography. Figures 5, 6 and 7 show that LS
(in addition to a standard set of LF tests and ultrasono-
graphy) can discriminate individuals at high risk for
non-alcoholic and alcoholic liver diseases.
While investigations of the pathogenesis of various
liver diseases are important, liver biopsies are not always
feasible because of adverse effects, and were unobtain-
able from our population from an ethical standpoint.
Nevertheless, our reference values for LS would be use-
ful to select candidates for liver biopsy and thus
decrease the rate of unnecessary procedures.
Conclusion
In conclusion, our study uncovered several factors that
are associated with LS, and showed that measuring LS is
a non-invasive, simple and efficient method of identify-
ing individuals at high risk for ALD and NAFLD. Future
Table 3 Results of univariate and multivariate logistic
regression analyses of factors affecting LS
Univariate Odds ratio 95% Cl P value
Sex 1
Female
Male 1.56 0.93-2.62 0.08
Age(years)
< 40 1
40-60 1.5 0.82-2.77 0.17
≥60 1.54 0.71-3.29 0.27
BMI(kg/m2)
< 23 1
23-25 2.52 1.23-5.01 0.012
> 25 3.26 1.65-6.34 0.0008
Alcohol(g/day)
0-20 1
> 20 2.12 1.23-3.70 0.0075
Abnormal LFT 3.88 2.17-6.94 < 0.0001
Fatty liver 5.55 3.11-9.88 < 0.0001
APRI 2.11 1.06-3.23 0.0001
Multivariate Odds ratio 95% CI P value
BMI 23-25 kg/m2 2.21 1.06-4.46 0.033
BMI > 25 kg/m2 3.25 1.62-6.43 0.001
Alcohol (g/day) 0.97 0.50-1.82 0.94
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studies should investigate pathological factors other than
fibrosis that influence LS in clinical populations.
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